MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 26, 2008; DOI: 10.1124/mol.108.045104


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.045104v1
73/6/1838    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zwart, R.
Right arrow Articles by Sher, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zwart, R.
Right arrow Articles by Sher, E.


Received for publication January 9, 2008.
Revised March 19, 2008.
Accepted for publication March 24, 2008.

Sazetidine-A is a potent and selective agonist at native and recombinant {alpha}4{beta}2 nicotinic acetylcholine receptors

Ruud Zwart 1*, Anna Lisa Carbone 2, Mirko Moroni 2, Isabel Bermudez 2, Adrian Mogg 1, Elizabeth Folly 3, Lisa Broad 1, Andrew Williams 1, Deyi Zhang 1, Chunjin Ding 1, Beverly Heinz 1, Emanuele Sher 1

1 Eli Lilly and Company 2 Oxford Brookes University 3 Ely Lilly and Company

* Address correspondence to: E-mail: zwart_ruud{at}lilly.com

Abstract

Sazetidine-A has been recently proposed to be a "silent desensitizer" of {alpha}4{beta}2 nicotinic acetylcholine receptors (nAChRs), implying that it desensitizes {alpha}4{beta}2 nAChRs without first activating them. This unusual pharmacological property of sazetidine-A makes it, potentially, an excellent research tool to distinguish between the role of activation and desensitization of {alpha}4{beta}2 nAChRs in mediating the CNS effects of nicotine itself, as well as those of new nicotinic drugs. Surprisingly, we found that sazetidine-A potently and efficaciously stimulates nAChR-mediated dopamine release from rat striatal slices, which is mediated by {alpha}4{beta}2* and {alpha}6{beta}2* nAChRs. The agonist effects on native striatal nAChRs prompted us to re-examine the effects of sazetidine-A on recombinant {alpha}4{beta}2 nAChRs in more detail. We expressed the two alternative stoichiometries of {alpha}4{beta}2 nAChR in Xenopus oocytes and investigated the agonist properties of sazetidine-A on both {alpha}4(2){beta}2(3) and {alpha}4(3){beta}2(2) nAChRs. We found that sazetidine-A potently activated both stoichiometries of {alpha}4{beta}2 nAChR: it was a full agonist on {alpha}4(2){beta}2(3) nAChRs, whereas it had an efficacy of only 6% on {alpha}4(3){beta}2(2) nAChRs. In contrast to what has been published before, we therefore conclude that sazetidine-A is an agonist of native and recombinant {alpha}4{beta}2 nAChRs while showing differential efficacy on {alpha}4{beta}2 nAChRs subtypes.


Key words: Nicotinic cholinergic, Func. analysis receptor/ion channel mutants, Receptor binding studies





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics